YBGJ · Yubo International Biotech Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $3.5K | - |
| Cost of Revenue | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $827 | - |
| Gross Profit | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $2.7K | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - |
| Total Operating Expenses | $289.3K | - | $310.1K | $249.7K | $467.3K | - | $532.8K | $470.4K | $412.1K | - |
| D&A | $25.7K | - | $41.9K | $41.7K | $41.3K | - | $46.0K | $41.4K | $43.3K | - |
| Operating Income | ($289.3K) | - | ($310.1K) | ($249.7K) | ($467.3K) | - | ($532.8K) | ($470.4K) | ($409.4K) | - |
| Interest Expense | - | - | $18 | $23 | - | - | $49 | $17 | $84 | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($272.6K) | - | ($310.2K) | ($230.3K) | ($435.6K) | - | ($621.1K) | ($598.3K) | ($409.5K) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | $0.00 | - | $0.00 | $0.00 | $0.00 | - | $0.00 | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.4K | $8.1K | $10.9K | $10.4K | $9.8K | $7.0K | $8.0K | $7.7K | $57.0K | $6.4K |
| Accounts Receivable | $134.2K | $138.0K | $114.3K | $118.0K | $146.7K | $165.0K | $218.0K | $210.6K | $114.7K | $79.7K |
| Inventory | $24.4K | $24.0K | $37.9K | $37.6K | $37.2K | $37.0K | $6.6K | $86.9K | $211.8K | $214.6K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $597.8K | $667.5K | $649.6K | $659.1K | $685.2K | $682.8K | $724.0K | $761.4K | $734.9K | $725.2K |
| Total Assets | $709.9K | $847.1K | $953.2K | $1.05M | $1.17M | $1.53M | $1.65M | $1.73M | $1.55M | $1.67M |
| Current Liabilities | $3.02M | $2.79M | $2.56M | $5.03M | $4.78M | $4.72M | $4.49M | $3.95M | $3.52M | $3.40M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.02M | $2.79M | $2.56M | $5.03M | $4.81M | $4.83M | $4.70M | $4.15M | $3.61M | $3.51M |
| Stockholders' Equity | ($2.30M) | ($1.95M) | ($1.66M) | ($4.00M) | ($3.67M) | ($3.42M) | ($3.13M) | ($2.52M) | ($2.07M) | ($1.84M) |
| Retained Earnings | ($8.01M) | ($7.74M) | ($7.48M) | ($7.33M) | ($7.10M) | ($6.66M) | ($6.37M) | ($5.79M) | ($5.26M) | ($4.89M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($207.2K) | - | - | - | ($392.0K) | - | - | - | ($120.4K) | - |
| Investing Cash Flow | $0 | - | - | - | ($6.2K) | - | - | - | ($30.0K) | - |
| Financing Cash Flow | $214.5K | - | - | - | $277.8K | - | - | - | $98.0K | - |
| CapEx | $0 | - | - | - | $6.2K | - | - | - | $18.9K | - |
| Free Cash Flow | ($207.2K) | - | - | - | ($398.2K) | - | - | - | ($139.3K) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | 76.3% | - |
| Operating margin | - | - | - | - | - | - | - | - | -11738.0% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -10496.5% | - |
| Net margin | - | - | - | - | - | - | - | - | -11740.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -3994.2% | - |
| FCF / Net income | 0.76 | - | - | - | 0.91 | - | - | - | 0.34 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -38.4% | - | -32.5% | -21.9% | -37.3% | - | -37.6% | -34.6% | -26.4% | - |
| Return on equity | 11.9% | - | 18.7% | 5.8% | 11.9% | - | 19.8% | 23.7% | 19.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.20 | 0.24 | 0.25 | 0.13 | 0.14 | 0.14 | 0.16 | 0.19 | 0.21 | 0.21 |
| Quick ratio | 0.19 | 0.23 | 0.24 | 0.12 | 0.14 | 0.14 | 0.16 | 0.17 | 0.15 | 0.15 |
| Cash ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | -17229.7x | -10856.5x | - | - | -10872.7x | -27672.7x | -4874.1x | - |
| Equity multiplier | -0.31 | -0.43 | -0.57 | -0.26 | -0.32 | -0.45 | -0.53 | -0.68 | -0.75 | -0.90 |
| Liabilities / Assets | 4.25 | 3.30 | 2.68 | 4.79 | 4.13 | 3.15 | 2.84 | 2.40 | 2.33 | 2.11 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | 12005d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | 93480d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | -100.0% | - | -100.0% | -100.0% | -97.8% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | -95.4% | - |
| Operating income growth (YoY) | 38.1% | - | 41.8% | 46.9% | -14.1% | - | - | -28.1% | -29.3% | - |
| Net income growth (YoY) | 37.4% | - | 50.1% | 61.5% | -6.4% | - | - | -62.9% | -29.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 48.0% | - | - | - | -185.8% | - | - | - | -326.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 37.4% | 42.9% | 46.9% | -58.5% | -77.6% | -85.7% | -184.4% | -119.3% | -146.3% | -226.1% |
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Yubo International Biotech Ltd against the 5 most active filers in the same SIC group.